Celgene’s Abraxane Scores A Win Against Tough Pancreatic Cancer
Executive Summary
Abraxane more than doubled two-year survival and conferred a near-two-month overall survival advantage against pancreatic cancer compared with standard of care gemcitabine alone in the Phase III MPACT trial, presented Jan. 25 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Celgene plans global regulatory filings by mid-2013.
You may also be interested in...
Celgene’s Budding Blockbuster Abraxane Scoops Pancreatic Cancer Indication
Abraxane sales have been growing fast as Celgene has added new indications. Pancreatic cancer had been an off-label use prior to the new approval.
Immune/EpiCept Merge To Form Multi-Project Antibody Drug Company
Israeli antibody drug developer Immune Pharmaceuticals will have several projects in the pipeline, including some potential out-licensing candidates, after it makes the leap to a U.S. public company through a reverse-merger with troubled EpiCept, CEO Daniel Teper said during an interview at BIO CEO.
Celgene Lays Out Catalysts For Strong 2013, Highlights Apremilast
Celgene reported strong sales for key products, led by Revlimid, during its year-end 2012 call. The biopharma affirmed 2013 guidance, detailing the key regulatory and commercial drivers that will power the global expansion of its hematology, oncology, and immunology franchises. In particular, it highlighted the commercial potential for apremilast.